Belite Bio (BLTE) and Its Competitors Head-To-Head Survey

Belite Bio (NASDAQ:BLTE) is one of 992 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its peers? We will compare Belite Bio to related companies based on the strength of its profitability, earnings, risk, analyst recommendations, dividends, valuation and institutional ownership.

Earnings and Valuation

This table compares Belite Bio and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Belite Bio	N/A	-$31.63 million	-30.06
Belite Bio Competitors	$1.68 billion	$149.77 million	-4.34

Belite Bio’s peers have higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Belite Bio and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-54.05%	-50.06%
Belite Bio Competitors	-2,613.34%	-229.90%	-29.69%

Risk and Volatility

Belite Bio has a beta of -1.62, indicating that its stock price is 262% less volatile than the S&P 500. Comparatively, Belite Bio’s peers have a beta of 0.85, indicating that their average stock price is 15% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings for Belite Bio and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	0	0	7	0	3.00
Belite Bio Competitors	5998	18433	43947	909	2.57

Belite Bio currently has a consensus target price of $44.83, suggesting a potential upside of 20.29%. As a group, “Pharmaceutical preparations” companies have a potential upside of 90.86%. Given Belite Bio’s peers higher probable upside, analysts plainly believe Belite Bio has less favorable growth aspects than its peers.

Institutional & Insider Ownership

0.5% of Belite Bio shares are held by institutional investors. Comparatively, 44.7% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 13.3% of Belite Bio shares are held by insiders. Comparatively, 14.2% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Belite Bio peers beat Belite Bio on 9 of the 13 factors compared.

Belite Bio Company Profile

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases (STGD1). Its lead product candidate is LBS-008 (Tinlarebant), an orally administered, once-a-day tablet for maintaining the health and integrity of retinal tissues in STGD1 and GA patients. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, and gout, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.